BioNTech SE

NasdaqGS:BNTX Stock Report

Market Cap: US$23.3b

BioNTech Balance Sheet Health

Financial Health criteria checks 5/6

BioNTech has a total shareholder equity of €19.2B and total debt of €37.1M, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are €22.0B and €2.8B respectively.

Key information

0.19%

Debt to equity ratio

€37.10m

Debt

Interest coverage ration/a
Cash€13.74b
Equity€19.22b
Total liabilities€2.76b
Total assets€21.99b

Recent financial health updates

Does BioNTech (NASDAQ:BNTX) Have A Healthy Balance Sheet?

Jul 01
Does BioNTech (NASDAQ:BNTX) Have A Healthy Balance Sheet?

Recent updates

BioNTech: The Market Is Pricing Low Oncology Success

Feb 25

BioNTech SE's (NASDAQ:BNTX) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jan 28
BioNTech SE's (NASDAQ:BNTX) Price Is Right But Growth Is Lacking After Shares Rocket 26%

The BioNTech SE (NASDAQ:BNTX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 08
The BioNTech SE (NASDAQ:BNTX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Does BioNTech (NASDAQ:BNTX) Have A Healthy Balance Sheet?

Jul 01
Does BioNTech (NASDAQ:BNTX) Have A Healthy Balance Sheet?

BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment

Mar 17
User avatar

Advancing Oncology Pipeline May Drive Future Growth Amid Near-Term Earnings Pressure

Promising oncology assets, improved R&D efficiencies, and strategic partnerships drive potential long-term revenue growth and shareholder value for BioNTech.

BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-Hold

Jan 23

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

Nov 06

BioNTech's Oncology Gamble: High Stakes, Big Potential

Oct 21

BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward

Aug 20

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

Aug 06

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

Jun 13

BioNTech Earnings Preview: I Will Stay On The Sidelines

May 03

Financial Position Analysis

Short Term Liabilities: BNTX's short term assets (€16.1B) exceed its short term liabilities (€2.1B).

Long Term Liabilities: BNTX's short term assets (€16.1B) exceed its long term liabilities (€622.1M).

Debt to Equity History and Analysis

Debt Level: BNTX has more cash than its total debt.

Reducing Debt: BNTX's debt to equity ratio has reduced from 11.4% to 0.2% over the past 5 years.

Debt Coverage: BNTX's debt is well covered by operating cash flow (1229.1%).

Interest Coverage: Insufficient data to determine if BNTX's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/09 19:22
End of Day Share Price 2026/04/09 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioNTech SE is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Harry GillisBerenberg
Samuel EnglandBerenberg